Bloomberg says Pfizer (NYSE: PFE) is delaying a sale of its nutrition business to consider a spinoff.

Reuters quotes the pharma giant's CFO, Frank D'Amelio, as saying that no decision has been reached yet.

I say don't worry about it.

The company already said it plans to get rid of its nutrition and animal-health business, but the structure of the divestment -- sale or spinout -- is still up in the air. If you're most interested in the long-term health of the pharmaceutical business, I think a sale is the best bet. The more cash firepower Pfizer has, the easier it'll be to restock its pipeline through licensing or acquisition deals.

But there are complications with a sale. First and foremost, you've got to find a buyer at a reasonable price. That might not be too hard for the nutrition business. Abbott Labs (NYSE: ABT), Danone, and Nestle are all reportedly interested, which should generate enough competition to keep the lowball bids away.

For the animal-health business, it could be trickier. There are various products for all the different farm animals and pets, and there are often only a couple of players selling each product, creating an antitrust nightmare for potential buyers. Merck (NYSE: MRK) and Sanofi (NYSE: SNY) failed to seal their deal to combine their animal-health divisions for just that reason.

Pfizer could IPO the assets; essentially, sell the divisions to new shareholders like Bristol-Myers Squibb (NYSE: BMY) did when it let go of Mead Johnson Nutrition (NYSE: MJN). Bristol actually did a combination of an IPO and a spinout, where the company retained many of the shares after the IPO and later allowed investors to trade Bristol shares in for Mead Johnson ones.

The biggest knock on a sale or IPO versus a straight spinout where every investor gets shares of the spinout is that the latter is usually tax-free for investors. If you're planning on holding onto both companies, it could be the best choice Pfizer could make (even if the company doesn't get any cash in the process).

Ultimately, you'll just have to wait for the number crunchers to finish their job and a decision to be made. Management has a fiduciary duty to do what's best for investors, so you'll just need to trust that they'll do the right thing. And if you don't, why do you own shares?

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Abbott Laboratories. Motley Fool newsletter services have recommended buying shares of Abbott Laboratories and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.